Zydus Cadila receives FDA blessing for generic Renvela
The Food and Drug Administration has granted clearance to Zydus Cadila for sevelamer carbonate tablets in a dosage strength of 800 mg.
The product is the generic of Sanofi-Aventis' Renvela and is indicated to for use by patients with chronic kidney disease who are on dialysis to control their phosphorus levels.
The drug is a phosphate binder that helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus.
It will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
